Cargando…

Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model

This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared to other BCG strains. BCG Tokyo > BCG TICE at i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tham, Sin Mun, Rahmat, Juwita N., Chiong, Edmund, Wu, Qinghui, Esuvaranathan, Kesavan, Mahendran, Ratha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698822/ https://www.ncbi.nlm.nih.gov/pubmed/34944584 http://dx.doi.org/10.3390/biomedicines9121766

Ejemplares similares

Tumor and Microenvironment Modification during Progression of Murine Orthotopic Bladder Cancer
por: Tham, Sin Mun, et al.
Publicado: (2011)

Tokyo-172 BCG Vaccination Complications, Taiwan
por: Jou, Ruwen, et al.
Publicado: (2009)

Bacillus Calmette-Guérin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival
por: Rahmat, Juwita N., et al.
Publicado: (2018)

Wirelessly Activated Nanotherapeutics for In Vivo Programmable Photodynamic‐Chemotherapy of Orthotopic Bladder Cancer
por: Sun, Bowen, et al.
Publicado: (2022)

Severe Osteomyelitis as a Complication of Tokyo-172 BCG Vaccination
por: Kwon, Hyo Jin, et al.
Publicado: (2012)

Lactobacillus rhamnosus GG Activation of Dendritic Cells and Neutrophils Depends on the Dose and Time of Exposure
por: Cai, Shirong, et al.
Publicado: (2016)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Growth inhibition of HeLa cell by internalization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Tokyo
por: Kitamura, Akira, et al.
Publicado: (2009)

Comparative Study of the Susceptibility to Oxidative Stress between Two Types of Mycobacterium bovis BCG Tokyo 172
por: Taniguchi, Keiichi, et al.
Publicado: (2021)

Pott's disease post intravesical BCG
por: Jain, Anika
Publicado: (2023)

The prominent alteration in transcriptome and metabolome of Mycobacterium bovis BCG str. Tokyo 172 induced by vitamin B(1)
por: Song, Ningning, et al.
Publicado: (2019)

Local Immune Stimulation by Intravesical Instillation of Baculovirus to Enable Bladder Cancer Therapy
por: Ang, Wei Xia, et al.
Publicado: (2016)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Results of the Tokyo Consensus Meeting Tokyo Guidelines
por: Mayumi, Toshihiko, et al.
Publicado: (2007)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

Case Presentation: Lung Consolidation as Sequelae of BCG Sepsis After Combined Intravesical and Intraurethral BCG
por: Strich, Jeffrey R., et al.
Publicado: (2017)

Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172
por: Wada, Takayuki, et al.
Publicado: (2015)

Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product
por: Hozouri, Hamidreza, et al.
Publicado: (2014)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Protective role of intravesical BCG in COVID-19 severity
por: Gallegos, Héctor, et al.
Publicado: (2021)

An uncommon cause of miliary disease: intravesical BCG immunotherapy
por: Azevedo, Marcelo, et al.
Publicado: (2021)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Focus on Tokyo
Publicado: (1978)

Tokyo Conference
Publicado: (1978)

Tokyo Trends
por: Low, Adrian F.
Publicado: (2022)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

BCGitis: A rare complication after intravesical BCG therapy
por: Oliveira, Maria João, et al.
Publicado: (2015)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Reactive Arthritis – A Rare Complication of Intravesical BCG Instillation
por: Freixa, Marta, et al.
Publicado: (2020)

Systemic Bacillus Calmette-Guérin (BCG) Infection and Accompanying Warm Autoimmune Haemolytic Anaemia Following Intravesical BCG Immunotherapy
por: Güven, Alper Tuna, et al.
Publicado: (2023)

Tokyo-Kyoto : Kiki Baron /

Cool shops Tokyo
Publicado: (2006)

Yevgeny Kissin in Tokyo
Publicado: (1990)

Historia de tokyo
Publicado: (1993)

A solitary pulmonary nodule caused by Mycobacterium tuberculosis var. BCG after intravesical BCG treatment: a case report
por: Itai, Mariko, et al.
Publicado: (2021)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Differential diagnosis of reactive arthritis in a patient with intravesical BCG immunotherapy
por: Aguridă, Aida Roxana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_trj7clckkctdnhd7ktk2g7rd9c